Northwire Canada EditionTuesday, August 25, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0% GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0%
M&A / Property Routine +

Ventripoint and Ollie Hinkle Heart Foundation Partner to Expand Access to AI-Powered Heart Imaging for Children Living with Heart Disease

AI cardiac imaging startup scaling niche partnerships while navigating a critical $55k cash balance and negative working capital.

By The Northwire Desk — AI Analysis Jun 26, 2026 · 08:10 VPT · 0.105 VentriPoint Diagnostics Ltd.
Executive Summary
  • Ventripoint Diagnostics announced a strategic collaboration with the Ollie Hinkle Heart Foundation (OHHF) to expand access to its AI-powered VMS+ cardiac imaging platform for pediatric and congenital heart disease patients.
  • OHHF will provide initial financial support to deploy two VMS+ systems within its healthcare partner network.
  • The partnership integrates OHHF’s "Take Heart Collective Impact Model" to align families, clinicians, and innovators, aiming to reduce barriers to advanced cardiac imaging and support patient monitoring.
  • The VMS+ platform uses AI to provide MRI-level volumetric measurements from standard echocardiograms and holds regulatory approvals in the U.S., Europe, and Canada.
Material Impact
  • The deployment of two systems is operationally incremental and does not materially impact revenue or cash flow given the company's FY2025 revenue of $179,928 CAD.
  • The partnership serves as a strategic validation for the company's focus on underserved pediatric/congenital markets, aligning with its broader commercialization and hub-and-spoke distribution strategy.
  • No new capital is raised, and the financial support is limited to initial deployment costs. The news does not alter the company's immediate liquidity constraints or debt obligations.
VPT · Price
Company Overview
  • Ventripoint Diagnostics Ltd. is a medical technology company commercializing the VMS+™ platform, an AI-driven software that converts standard 2D echocardiograms into highly accurate 3D volumetric heart models.
  • The technology aims to provide MRI-level diagnostic accuracy at the point of care, reducing reliance on costly and time-consuming cardiac MRIs.
  • The company is transitioning from a product development phase to a commercial execution phase, utilizing a Device-as-a-Service (DaaS) subscription model to shorten sales cycles and generate recurring revenue.
  • Target markets include congenital heart disease, heart failure, pulmonary hypertension, and cardiotoxicity monitoring, with a focus on underserved, remote, and Indigenous communities through hub-and-spoke deployment models.
Read the original news release →

More from VentriPoint Diagnostics Ltd.

Jun 16, 2026 · 09:11

AI cardiac imaging startup scales commercial partnerships but remains cash-constrained and pre-revenue at scale.

Other Apr 28, 2026 · 08:00

Ventripoint Advances China Entry Amidst Persistent Dilution Concerns

Regulatory Apr 20, 2026 · 08:50

Ventripoint Wins Gold Edison Award But Cash Burn and Dilution Risks Persist

Other Apr 16, 2026 · 11:00

TSXV Venture Exchange Listed Cardiac Imaging Platform

M&A / Property Apr 01, 2026 · 22:50

Ventripoint Diagnostics Announces Collaboration with the Health Division of the Montecristo Group

M&A / Property Mar 27, 2026 · 10:15

MedTech's Edge: How AI and Remote Diagnostics Drive Scalable Value

M&A / Property